---
title: "Abbott Laboratories (ABT) Gets a Buy from Raymond James"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293128634.md"
description: "Raymond James analyst Jayson Bedford maintained a Buy rating on Abbott Laboratories (ABT) in a July 17 report, citing the stock's recent close at $100.68. The company holds a Strong Buy consensus with an average price target of $119.31, implying 18.5% upside. Additionally, Citi reaffirmed its Buy rating with a $112 price target."
datetime: "2026-07-19T15:25:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293128634.md)
  - [en](https://longbridge.com/en/news/293128634.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293128634.md)
---

# Abbott Laboratories (ABT) Gets a Buy from Raymond James

In a report released on July 17, Jayson Bedford from Raymond James maintained a Buy rating on Abbott Laboratories. The company’s shares closed last Friday at $100.68.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Bedford is a 5-star analyst with an average return of 8.6% and a 59.56% success rate. Bedford covers the Healthcare sector, focusing on stocks such as AxoGen, Dexcom, and Insulet.

Abbott Laboratories has an analyst consensus of Strong Buy, with a price target consensus of $119.31, which is a 18.50% upside from current levels. In a report released on July 17, Citi also maintained a Buy rating on the stock with a $112.00 price target.

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [AXGN.US](https://longbridge.com/en/quote/AXGN.US.md)
- [DXCM.US](https://longbridge.com/en/quote/DXCM.US.md)
- [PODD.US](https://longbridge.com/en/quote/PODD.US.md)

## Related News & Research

- [Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades](https://longbridge.com/en/news/293449087.md)
- [Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall](https://longbridge.com/en/news/293792909.md)
- [These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results](https://longbridge.com/en/news/293046426.md)
- [23:20 ETPRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records](https://longbridge.com/en/news/293695963.md)
- [Ironwood Investment Counsel LLC Purchases Shares of 11,963 Abbott Laboratories $ABT](https://longbridge.com/en/news/293194413.md)